ANCORA INNOVATIONS – Vanderbilt University | Deerfield

REQUEST FOR APPLICATIONS

Rare Genetic Diseases

Opening January 2021

Rolling Submission-Review

Ancora Innovations is a collaboration between Vanderbilt University and Deerfield Management, focused on the union of Vanderbilt’s innovative life science discovery efforts and Deerfield’s commitment to accelerating state-of-the-art drug development. Deerfield will fund Ancora Innovation with up to $65 million to pursue novel therapeutics and will provide additional capital to fund successful start-up companies that spin out of Ancora.

Ancora Innovations is currently requesting proposals to develop innovative therapeutic strategies to rare genetic diseases.

All rare diseases with a known genetic cause that can be diagnosed with the aid of clinical sequencing are eligible. Preference is given to diseases with existing patient communities and clear clinical measures.

Each therapeutic discovery project supported by this funding opportunity must focus on a clear therapeutic hypothesis enabled by genetic and biological understanding of disease pathophysiology with cellular and in vivo models available. Existing therapeutic candidates are not required.

Therapeutics of interest include small molecules, biopharmaceuticals, and gene therapies.

To create a profile with Ancora Innovations and learn more about the Letter of Intent application, please click here.

Interested faculty should email Margaret Read (margaret.a.read@vanderbilt.edu) to learn more about next steps and formal submission.

Ancora will be hosting an Information Session, Accelerating the Commercialization of Transformative Biomedical Technologies with a Focus On Rare Genetic Diseases, on Thursday January 21, 2020 at 10:00 am CT / 11:00 am ET. Interested attendees should register here to RSVP.

Thank you.

Supported By: